Metformin, a medication initially developed to treat type 2 diabetes, remains a frequently prescribed treatment for Polycystic Ovary Syndrome (PCOS) despite limited regulatory approvals for that specific indication. While widely used, approvals exist only in a few countries, including for the originator, Glucophage®, according to recent reports.
PCOS is the most common endocrine disorder affecting women of reproductive age, characterized by anovulation, hyperandrogenism and often, morphological changes in the ovaries. A key factor in the development of PCOS is insulin resistance (IR), frequently accompanied by compensatory hyperinsulinemia. This insulin resistance likely contributes to the elevated androgen levels often seen in women with the syndrome, according to research published in PubMed.
Metformin’s role in managing PCOS centers on its ability to improve the body’s response to insulin. This improvement can lead to more regular menstrual cycles, support ovulation, and reduce symptoms associated with high androgen levels, such as acne and excessive hair growth. Although not specifically approved by the Food and Drug Administration for PCOS treatment, it is considered a first-line therapy by many physicians.
Studies have demonstrated that metformin can significantly reduce serum androgen levels and restore menstrual cyclicity, potentially aiding in the treatment of PCOS-related infertility. The drug’s mechanism of action involves improving insulin sensitivity, which in turn can positively impact hormonal imbalances associated with PCOS. Research indicates that metformin may be particularly useful in addressing infertility challenges linked to the condition.
The prevalence of PCOS varies geographically, with some studies focusing on specific regions. For example, research has examined the syndrome’s prevalence in Saudi Arabia, highlighting the need for localized data to understand the scope of the condition and tailor treatment approaches. The condition affects both obese and non-obese women, indicating that insulin resistance plays a significant role regardless of body mass index.
Despite its widespread use, the regulatory landscape surrounding metformin for PCOS remains fragmented. The lack of broad regulatory approval raises questions about standardized treatment protocols and potential variations in patient care across different healthcare systems. Further research and regulatory clarity are needed to optimize the use of metformin in PCOS management.
